Trials / Terminated
TerminatedNCT03052400
Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Charles Drew University of Medicine and Science · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome
Detailed description
Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome, and sub-optimally controlled on basal insulin, with or without prandial insulin and/or maximally-tolerated doses of metformin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mifepristone 600 mg daily | Glucocorticoid receptor antagonist |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2017-02-03
- Primary completion
- 2021-03-31
- Completion
- 2021-05-31
- First posted
- 2017-02-14
- Last updated
- 2023-05-18
- Results posted
- 2022-10-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03052400. Inclusion in this directory is not an endorsement.